Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment

Traders Union
All News
Companies
Camp4 Therapeutics targets SYNGAP1 with ASOs

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Billionaires

Companies

Regulators News

Jose Antonio Gastelum

02.03.2026

Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment — Camp4 Therapeutics targets SYNGAP1 with ASOs

Camp4 Therapeutics Corp will present a novel method using antisense oligonucleotides (ASOs) to enhance gene expression and potentially treat diseases such as SYNGAP1 at the Keystone Symposium’s Epigenetics and Gene Regulation in Health and Disease Conference.

Alla Sigova, PhD, SVP of Platform at Camp4 Therapeutics Corp, will outline how the company leverages ASOs to target regulatory RNAs, paving the way for more precise and effective gene modulation. The presentation is expected to highlight the promise of this innovation in addressing complex genetic disorders.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

How precious-metals mining revival is reshaping portfolios in 2026

By Ciaran Ryan
12 hours ago

How precious-metals mining revival is reshaping portfolios in 2026

Editors' Picks

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

By Mikhail Vnuchkov
16 hours ago

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

Editors' Picks

Five years with Bitcoin: How El Salvador changed after legalizing BTC

By Eugene Komchuk
Yesterday

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Editors' Picks

All Editors' Top Picks

Latest CAMP4 News

Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy

By Elena Nikulina
21.05.2026

Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy

Companies

Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston

By Ivan Andriyenko
14.05.2026

Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston

Companies

Camp4 Therapeutics Corp targets capital discipline with new R and D focus

By Oleg Tkachenko
11.05.2026

Camp4 Therapeutics Corp targets capital discipline with new R and D focus

Companies

Ciaran Ryan
12 hours ago

How precious-metals mining revival is reshaping portfolios in 2026

Mikhail Vnuchkov
16 hours ago

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

Eugene Komchuk
Yesterday

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Anastasiia Chabaniuk
09.06.2026

Crypto on the court: How NBA Finals became a showcase for Ledger

Johnathan Maverick
08.06.2026

How to build wealth from scratch in 3 practical steps

Yaroslav Dmytrenko
4 min ago

Alex Svanevik: Ads fund token rewards as users wait for AI build

Olga Shendetskaya
15 min ago

SpaceX IPO prompts focus on first year after listing, Sonali Basak analyzes

Andreas Kristo
35 min ago

CPI inflation cycles average 5.31 years, Tom McClellan notes

Artem Shendetskii
50 min ago

Mario Nawfal: Market adds $1.15 trillion fueled by Iran peace news

Ivan Andriyenko
1 hour ago

Europe should anchor inflation expectations and pursue reforms, Kristalina Georgieva notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Ivan Andriyenko
10 hours ago

U.S. gas exports gain ground in India as Gulf supplies falter

U.S. gas exports gain ground in India as Gulf supplies falter

Parshwa Turakhiya
12 hours ago

Japan crypto bill moves closer to final passage

Japan crypto bill moves closer to final passage

Igor Krasulya
13 hours ago

Inflation pressure pushes ECB toward rate hike

Inflation pressure pushes ECB toward rate hike

Eugene Komchuk
13 hours ago

Police investigate Bithumb chief over hiring of lawmaker's son

Police investigate Bithumb chief over hiring of lawmaker's son

Andrey Mastykin
15 hours ago

U.S. strikes on Iran send Wall Street futures higher

U.S. strikes on Iran send Wall Street futures higher

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Google doubles down on AI amid stock pressure and regulatory risks

Anton Kharitonov
Now

Microsoft breaks support as pressure on shares intensifies

Mykhailo Ihnatenko
Now

Silver rebounds as Middle East tensions revive safe-haven demand

Anton Kharitonov
Now

Apple remains under pressure despite strong fundamentals

Mykhailo Ihnatenko
Now

AI stocks face first major liquidity test

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.